Compare BridgeBio Pharma Inc (BBIO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Uranium Energy Corp — how do they compare? BridgeBio Pharma Inc trades at $82.33 (market cap $16.46B), while Uranium Energy Corp trades at $10.17 (market cap $5.14B). The key difference: BridgeBio Pharma Inc is far larger — about 3.2× Uranium Energy Corp's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals.
| BBIO | UEC | |
|---|---|---|
Market Cap | $16.46B | $5.14B |
Sector | Health | Energy |
52-Week High | $90.17 | $20.14 |
52-Week Low | $44.81 | $6.98 |
Enterprise Value | $18.02B | $4.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
Uranium Energy (UEC) trades at $10.07, down 4.37% today, reflecting ongoing operational challenges. The stock shows a bearish technical trend with key support at $10. Fundamentally, the company reported a net loss of $87.66 million in 2025 on $66.84 million revenue, with negative margins and a high P/S ratio of 242.83. Recent news highlights strategic positioning in U.S. uranium production but notes execution risks and cost pressures.
The outlook remains speculative; UEC's $794 million liquidity and debt-free balance sheet support growth initiatives, but persistent losses and volatile earnings create significant risk. Analyst consensus is 87.5% buy, targeting production ramp-ups, yet investors face uncertainty from licensing delays and uranium price fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
